ReportWire

Tag: medical insurance

  • The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks

    The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks

    [ad_1]

    The Russell 2000 Index soared 12% in December, which might reflect investors’ exuberance about the state of the U.S. economy — it appears the Federal Reserve has won its battle against inflation.

    But if you are looking to broaden your exposure to the stock market beyond the large-cap S&P 500
    SPX,
    buying shares of a fund that tracks the Russell 2000 Index
    RUT
    might not be the best way to do it. This is because the Russell 2000 isn’t selective — it is made up of the smallest 2,000 companies by market capitalization in the Russell 3000 Index
    RUA,
    which itself is designed to capture about 98% of the U.S. public equity market.

    A better choice might be the S&P Small Cap 600 Index
    SML
    because S&P Global requires companies to show four consecutive quarters of profitability to be initially included in the index, among other criteria.

    Below is a screen of analysts’ favorite stocks among the S&P Small Cap 600, along with another for the Russell 2000.

    Watch for a “head fake”

    Much of the small-cap buying in December might have resulted from covering of short positions by hedge-fund managers. This idea is backed by the timing of trading activity immediately following the Federal Open Market Committee’s announcement on Dec. 13 that it wouldn’t change its interest-rate policy, according to MacroTourist blogger Kevin Muir. The Fed’s economic projections released the same day also indicate three cuts to the federal-funds rate in 2024.

    Heading into the end of the year, a fund manager who had shorted small-caps, and then was surprised by the Fed’s interest-rate projections, might have scrambled to buy stocks it had shorted to close-out the positions and hopefully lock in gains, or limit losses.

    That buying activity and resulting pop in small-cap prices could set up a typical “head fake” for investors as the new year begins, according to Muir.

    The long-term case for quality

    Looking at data for companies’ most recently reported fiscal quarters, 58% of the Russell 2000 reported positive earnings per share, according to data provided by FactSet. In other words, hundreds of these companies were losing money. These might include promising companies facing “binary events,” such as make-or-break drug trials in the biotechnology industry.

    In comparison, 78% of companies among the S&P Small Cap 600 were profitable, and 93% of the S&P 500 were in the black.

    Here are long-term performance figures for exchange-traded funds that track all three indexes:

    ETF

    Ticker

    2023

    3 years

    5 years

    10 years

    15 years

    20 years

    iShares Russell 2000 ETF

    IWM 17%

    7%

    61%

    99%

    428%

    365%

    iShares Core S&P Small Cap ETF

    IJR 16%

    25%

    69%

    129%

    540%

    515%

    SPDR S&P 500 ETF Trust

    SPY 26%

    34%

    108%

    210%

    629%

    527%

    Source: FactSet

    An approach tracking the S&P Small Cap 600 has outperformed the Russell 2000 for all periods, with margins widening as you go further back.

    Brett Arends: You own the wrong small-cap fund. How to get into a better one.

    Looking ahead for quality… or not

    For the first screen, we began with the S&P Small Cap 600 and narrowed the list to 385 companies covered by at least five analysts polled by FactSet. Then we cut the list to 92 companies with “buy” or equivalent ratings among at least 75% of the covering analysts.

    Here are the 20 remaining stocks among the S&P Small Cap 600 with the highest 12-month upside potential indicated by analysts’ consensus price targets:

    Company

    Ticker

    Share “buy” ratings

    Dec. 29 price

    Consensus price target

    Implied 12-month upside potential

    Vir Biotechnology Inc.

    VIR,
    +4.47%
    88%

    $10.06

    $32.00

    218%

    Arcus Biosciences Inc.

    RCUS,
    +3.04%
    82%

    $19.10

    $41.00

    115%

    Xencor Inc.

    XNCR,
    +6.03%
    92%

    $21.23

    $39.83

    88%

    Dynavax Technologies Corp.

    DVAX,
    +2.86%
    100%

    $13.98

    $24.80

    77%

    ModivCare Inc.

    MODV,
    +0.95%
    100%

    $43.99

    $75.50

    72%

    Xperi Inc

    XPER,
    +1.81%
    80%

    $11.02

    $18.20

    65%

    Thryv Holdings Inc.

    THRY,
    100%

    $20.35

    $32.75

    61%

    Ligand Pharmaceuticals Inc.

    LGND,
    +1.25%
    100%

    $71.42

    $114.80

    61%

    Green Plains Inc.

    GPRE,
    -1.67%
    80%

    $25.22

    $40.30

    60%

    Patterson-UTI Energy Inc.

    PTEN,
    +0.28%
    75%

    $10.80

    $17.00

    57%

    Ironwood Pharmaceuticals Inc. Class A

    IRWD,
    +8.48%
    83%

    $11.44

    $17.83

    56%

    Catalyst Pharmaceuticals Inc.

    CPRX,
    +1.78%
    100%

    $16.81

    $26.20

    56%

    Payoneer Global Inc.

    PAYO,
    -3.45%
    100%

    $5.21

    $8.00

    54%

    Helix Energy Solutions Group Inc.

    HLX,
    -2.63%
    83%

    $10.28

    $15.00

    46%

    Arlo Technologies Inc.

    ARLO,
    -3.05%
    100%

    $9.52

    $13.80

    45%

    Pacira Biosciences Inc.

    PCRX,
    -5.16%
    100%

    $33.74

    $48.40

    43%

    Privia Health Group Inc.

    PRVA,
    +2.95%
    100%

    $23.03

    $32.53

    41%

    Semtech Corp.

    SMTC,
    -1.23%
    92%

    $21.91

    $30.90

    41%

    Talos Energy Inc.

    TALO,
    +1.19%
    78%

    $14.23

    $20.00

    41%

    Digi International Inc.

    DGII,
    -1.21%
    100%

    $26.00

    $36.14

    39%

    Source: FactSet

    Any stock screen should only be considered a starting point. You should do your own research to form your own opinion before making any investment. one way to begin is by clicking on the tickers for more about each company.

    Click here for Tomi Kilgore’s detailed guide to the wealth of information available for free on the MarketWatch quote page.

    Moving on to the Russell 2000, when we narrowed this group to stocks covered by at least five analysts polled by FactSet, we were left with 936 companies. Among these, 355 have “buy” or equivalent ratings among at least 75% of the covering analysts.

    Among those 355 stocks in the Russell 2000, these 20 have the highest implied upside over the next year, based on consensus price targets:

    Company

    Ticker

    Share “buy” ratings

    Dec. 29 price

    Consensus price target

    Implied 12-month upside potential

    Karyopharm Therapeutics Inc.

    KPTI,
    +4.18%
    75%

    $0.87

    $6.00

    594%

    Rallybio Corp.

    RLYB,
    +0.42%
    100%

    $2.39

    $16.50

    590%

    Vor Biopharma Inc.

    VOR,
    -0.89%
    100%

    $2.25

    $15.44

    586%

    Tenaya Therapeutics Inc.

    TNYA,
    -0.62%
    100%

    $3.24

    $19.14

    491%

    Compass Therapeutics Inc.

    CMPX,
    -5.13%
    86%

    $1.56

    $9.17

    488%

    Vigil Neuroscience Inc.

    VIGL,
    +2.66%
    88%

    $3.38

    $18.75

    455%

    Trevi Therapeutics Inc.

    TRVI,
    -2.99%
    100%

    $1.34

    $7.33

    447%

    Inozyme Pharma Inc.

    INZY,
    +1.64%
    100%

    $4.26

    $21.00

    393%

    Gritstone bio Inc.

    GRTS,
    +6.86%
    100%

    $2.04

    $10.00

    390%

    Actinium Pharmaceuticals Inc.

    ATNM,
    +4.72%
    83%

    $5.08

    $23.36

    360%

    Lineage Cell Therapeutics Inc.

    LCTX,
    86%

    $1.09

    $4.83

    343%

    Century Therapeutics Inc.

    IPSC,
    +9.64%
    86%

    $3.32

    $14.67

    342%

    Acrivon Therapeutics Inc.

    ACRV,
    +1.83%
    100%

    $4.92

    $21.13

    329%

    Avidity Biosciences Inc.

    RNA,
    +1.22%
    100%

    $9.05

    $37.50

    314%

    Longboard Pharmaceuticals Inc.

    LBPH,
    +316.25%
    100%

    $6.03

    $24.17

    301%

    Omega Therapeutics Inc.

    OMGA,
    -1.33%
    100%

    $3.01

    $12.00

    299%

    Allogene Therapeutics Inc.

    ALLO,
    +12.77%
    82%

    $3.21

    $12.79

    298%

    X4 Pharmaceuticals Inc.

    XFOR,
    +5.21%
    86%

    $0.84

    $3.26

    289%

    Caribou Biosciences Inc.

    CRBU,
    -2.79%
    89%

    $5.73

    $22.25

    288%

    Stoke Therapeutics Inc.

    STOK,
    +11.41%
    78%

    $5.26

    $19.33

    268%

    Source: FactSet

    That’s right — this Russell 2000 list is all biotech. And in case you are wondering if any companies are on both lists, the answer is no.

    Don’t miss: 11 dividend stocks with high yields expected to be well supported in 2024 per strict criteria

    [ad_2]

    Source link

  • WSJ News Exclusive | Cigna Calls Off Humana Pursuit, Plans Big Stock Buyback

    WSJ News Exclusive | Cigna Calls Off Humana Pursuit, Plans Big Stock Buyback

    [ad_1]

    Updated Dec. 10, 2023 4:47 pm ET

    Cigna Group abandoned its pursuit of a tie-up with Humana after shareholders balked at a deal that would have created a roughly $140 billion giant in the health-insurance industry.

    The companies couldn’t come to agreement on price and other financial terms, according to people familiar with the matter. In the near term, Cigna is turning its focus toward smaller, so-called bolt-on, acquisitions.

    Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

    [ad_2]

    Source link

  • Pharmacy Giant Walgreens Names Tim Wentworth as New CEO

    Pharmacy Giant Walgreens Names Tim Wentworth as New CEO

    [ad_1]

    Pharmacy Giant Walgreens Names Tim Wentworth as New CEO

    [ad_2]

    Source link

  • Rising health costs could make it harder for the Fed to get inflation down to 2%

    Rising health costs could make it harder for the Fed to get inflation down to 2%

    [ad_1]

    The rate of U.S. inflation has slowed considerably from a 40-year peak of 9.1% in mid-2022 and it’s gotten an assist from a surprising source: falling medical costs.

    But that’s about to end — to a large degree because of the complex way the federal government tries to figure the rise of medical costs. And a re-acceleration in health-care costs could complicate the Federal Reserve’s job to get inflation back down to pre-pandemic levels of 2% or less.

    “Unfortunately, the bill is about to become due” said economist Omair Sharif, founder of research firm Inflation Insights. “It’s going to be more of a headache for the Fed.”

    Ever-rising medical costs

    Rising medical costs have long been one of the biggest sources of inflation, even in times when overall U.S. prices were growing slowly. Medical costs rose an average of 3% a year in the decade prior to the pandemic and even faster in the early 2000s.

    Expensive health care was one the chief drivers of former President Barack Obama’s attempt to create a national health care system more than a decade ago.

    Yet medical costs began to decelerate sharply about one year ago, and in July, they turned negative for the first time since Word War Two. At least according to the complicated formula by which the federal government measures these expenses.

    The consumer price index, the nation’s main inflation gauge, showed that the annual cost of medical care fell by 1% in the 12 months ended in August. Less than a year before, they were rising at a 6% pace.

    Now, no one really believes medical costs are falling. Historically prices rise every year. And just this week The Wall Street Journal reported that health insurance could post the biggest price increase in 2024 in more than a decade.

    So what’s going on?

    Well, the government’s method for determining health-care prices has always been flawed — and the pandemic only made the problem worse. Far worse.

    The cost of health care is almost impossible to measure accurately, economists say. It’s easy to determine the price of gas or a loaf of bread. Not so the cost of a trip to the emergency room or even a routine visit to one’s doctor.

    Prices charged by doctors and hospitals are opaque, for one thing, and differ sharply even in the same city. It’s also difficult to gauge patient outcomes. And payments for services rendered are split by businesses, consumers and government (Medicare and Medicaid).

    “How do you measure outcomes? Is it an hour in the hospital? Is it making a patient healthy,” said Stephen Stanley, chief economist at Santander Capital Markets. “How do you measure any of this?”

    Then came the pandemic

    The government had to come up with a workaround, and it did.

    Basically the CPI formula subtracts the cost of benefits paid by health insurers on behalf of customers from the amount of premiums they pay. Whatever profits are leftover each year — known as retained earnings — are used to determine how much health-care prices are rising.

    The formula works all right in normal times, but the coronavirus threw a huge curve ball.

    Americans stopped going to the hospital or doctor’s office during Covid for fear of catching the virus. Health insurers paid out far less in benefits and profits soared.

    As the pandemic faded and Americans went back to their doctors, health insurers had to pay much more in benefits and profits sank.

    The result: Health-care costs as measured by the CPI have shown unprecedented ups and downs since the pandemic, especially since the government only updates its math for the medical index once a year in October.

    Just how big are these swings?

    The annual cost of health insurance in the CPI soared by a reported 28% as of September 2022, only to sink by 33% as of August.

    Now here comes another swing. Health insurance costs are set to rise sharply starting in October after the government’s next update to its CPI formula.

    That could spell trouble for the Fed.

    The ‘core’ of the problem

    The goal of the central bank is to get inflation back down to 2%, especially the core rate that strips out volatile food and energy costs.

    The core rate of the CPI already slowed considerably in the past year, decelerating to a yearly pace of 4.3% last month from a four-decade peak of 6.6% in mid-2022.

    The supposed plunge in health-insurance costs helped pave the way.

    At Inflation Insights, Shariff estimates the core CPI would have slowed to only 5.1% — not 4.3% — if health-care costs had risen in the past 11 months as fast as they were rising in September 2022.

    What about in the year ahead, when health insurance costs accelerate in the CPI? Medical care is the third biggest category in the index after housing and groceries.

    Economists are split how much it could impede the Fed in its effort to get inflation down to 2%.

    Shariff, for his part, thinks rising medical costs could add three-tenths or more to core CPI by next spring.

    “It’s going to start adding back to core inflation,” he said.

    At Santander Capital Markets, Stanley was one of the first Wall Street
    DJIA
    economists to warn about high inflation a few years ago. He is less sure rising medical costs will undermine the Fed’s inflation fight. “It is a really important category, but it’s probably not getting worked up about.”

    Other economists believe inflation is likely to continue to slow toward 2% largely because of easing price pressures in many other major categories such as food and especially shelter.

    Rents have come off a boil, for example, and housing prices aren’t rising rapidly anymore. Shelter accounts for more than one-third of the CPI versus a little over 8% for medical costs.

    “CPI only barely starting to show the slowdown in shelter costs,” said Simona Mocuta, chief economist at State Street Global Advisors.

    An alternative approach

    Senior economist Aichi Amemiya at Nomura said it’s better to focus on a separate measure of health-care costs preferred by the Fed that shows more stability.

    The health-service gauge found in the so-called PCE index shows that costs are rising about about 2.5% a year.

    “The PCE is the best measure to look at,” Amemiya said. “It’s designed to capture the total cost of health care.”

    The PCE tries to take into account total health-care spending, including business contributions to employee health insurance as well as Medicaid and Medicare reimbursement rates.

    As of July, the core PCE was up at an annual rate of 4.2%, almost the same as core CPI.

    Whatever the case, the cost of health care and its impact on inflation still bear watching.

    The massive ups and downs in the CPI health-insurers index has even forced the Bureau of Labor Statistics to rejigger its once-a-year formula to try to be more timely and accurate.

    Whether it can truly capture the changes in medical costs is still an open question.

    “I don’t think there is an easy answer on this,” Stanley said.

    [ad_2]

    Source link

  • FDA approves Alzheimer’s treatment Leqembi, clearing the way for Medicare coverage

    FDA approves Alzheimer’s treatment Leqembi, clearing the way for Medicare coverage

    [ad_1]

    The U.S. Food and Drug Administration on Thursday granted full approval to the Biogen BIIB and Eisai Co. Ltd. ESALF Alzheimer’s treatment Leqembi, a step that secures Medicare reimbursement for the first drug shown to slow the progress of the disease, rather than just treating its symptoms.

    Leqembi, also known as lecanemab, is a monoclonal antibody designed to reduce the buildup of amyloid beta plaque in the brain, a marker of Alzheimer’s disease.

    The…

    [ad_2]

    Source link

  • JPMorgan Chase, Delta, Inflation Data, the Fed, and More to Watch This Week

    JPMorgan Chase, Delta, Inflation Data, the Fed, and More to Watch This Week

    [ad_1]

    First-quarter earnings season kicks off this week. Results from big U.S. banks later in the week will be heavily scrutinized for the impact of the past month’s turmoil in the sector. Economic-data highlights will include the latest inflation data and minutes from the Federal Open Market Committee’s late-March meeting.



    Albertsons


    and


    CarMax


    will report on Tuesday, followed by


    Delta Air Lines


    and


    Fastenal


    on Thursday. Things pick up on Friday:


    Citigroup



    JPMorgan Chase



    Wells Fargo



    BlackRock


    and


    UnitedHealth Group


    are all scheduled to release their first-quarter results.

    [ad_2]

    Source link

  • These 20 stocks were the biggest winners of 2022

    These 20 stocks were the biggest winners of 2022

    [ad_1]

    Even during a year in which the S&P 500 index declined 19%, with 72% of its stocks in the red, there were plenty of winners.

    Before showing you the list of the best performers in the benchmark index, let’s look at a preview: Here’s how the 11 sectors of the S&P 500
    SPX,
    -0.25%

    performed for the year:

    Index

    2022 price change

    Forward P/E

    Forward P/E as of Dec. 31, 2021

    Energy

    59.0%

    9.7

    11.1

    Utilities

    -1.4%

    18.9

    20.4

    Consumer Staples

    -3.2%

    21.0

    21.8

    Health Care

    -3.6%

    17.6

    17.2

    Industrials

    -7.1%

    18.3

    20.8

    Financials

    -12.4%

    11.9

    14.6

    Materials

    -14.1%

    15.8

    16.6

    Real Estate

    -28.4%

    16.5

    24.2

    Information Technology

    -28.9%

    20.1

    28.1

    Consumer Discretionary

    -37.6%

    21.3

    33.2

    Communication Services

    -40.4%

    14.3

    20.8

    S&P 500

    -19.4%

    16.8

    21.4

    Source: FactSet

    Maybe you aren’t surprised to see that the energy sector was the only one to increase during 2022. But it might surprise you to see that despite the sector’s weighted price increase of 59%, its forward price-to-earnings ratio declined and remains very low relative to all other sectors.

    It might also surprise you that West Texas Intermediate crude oil
    CL.1,
    +2.69%

    gave up most of its gains from earlier in the year:


    FactSet

    The reason investors are still confident in energy stocks is that oil producers have remained cautious when it comes to capital spending. They don’t want to increase supply enough to cause prices to crash, as they did in the run-up to the summer of 2014, after which prices fell steadily through early 2016, causing bankruptcies and consolidation in the industry.

    Now the oil companies are focusing on maintaining supply, raising dividends and buying back shares, as Occidental Petroleum Corp.’s
    OXY,
    +1.14%

    chief executive explained in a recent interview with Matt Peterson. Click here for more about Occidental and the long-term supply/demand outlook for oil.

    Best-performing S&P 500 stocks of 2022

    Here are the 20 stocks in the benchmark index that rose most during 2022, excluding dividends. Proving that there are always exceptions, not all of them are in the energy sector.

    Company

    Ticker

    Sector

    Industry

    2022 price change

    Occidental Petroleum Corp.

    OXY,
    +1.14%
    Energy

    Oil & Gas Production

    117.3%

    Hess Corp.

    HES,
    +0.68%
    Energy

    Oil & Gas Production

    91.6%

    Marathon Petroleum Corp.

    MPC,
    +0.18%
    Energy

    Oil Refining/ Marketing

    81.9%

    Exxon Mobil Corp.

    XOM,
    +1.01%
    Energy

    Integrated Oil

    80.3%

    Schlumberger Ltd.

    SLB,
    +1.04%
    Energy

    Contract Drilling

    78.5%

    APA Corp.

    APA,
    +1.68%
    Energy

    Integrated Oil

    73.6%

    Halliburton Co.

    HAL,
    +1.23%
    Energy

    Oil & Gas Production

    72.1%

    First Solar Inc.

    FSLR,
    +0.68%
    Information Technology

    Semiconductors

    71.9%

    Valero Energy Corp.

    VLO,
    +0.43%
    Energy

    Oil Refining/ Marketing

    68.9%

    Marathon Oil Corp.

    MRO,
    +1.08%
    Energy

    Oil & Gas Production

    64.9%

    ConocoPhillips

    COP,
    +1.38%
    Energy

    Oil & Gas Production

    63.5%

    Steel Dynamics Inc.

    STLD,
    -0.72%
    Materials

    Steel

    57.4%

    EQT Corp.

    EQT,
    -0.12%
    Energy

    Oil & Gas Production

    55.1%

    Chevron Corp.

    CVX,
    +0.66%
    Energy

    Integrated Oil

    53.0%

    McKesson Corp.

    MCK,
    Health Care

    Medical Distributors

    50.9%

    Cardinal Health Inc.

    CAH,
    -0.46%
    Health Care

    Medical Distributors

    49.3%

    EOG Resources Inc.

    EOG,
    +0.69%
    Energy

    Oil & Gas Production

    45.8%

    Enphase Energy Inc.

    ENPH,
    -0.20%
    Information Technology

    Semiconductors

    44.8%

    Merck & Co. Inc.

    MRK,
    +0.12%
    Health Care

    Pharmaceuticals

    44.8%

    Cigna Corp.

    CI,
    +0.19%
    Health Care

    Managed Health Care

    44.3%

    Source: FactSet

    Click on the tickers for more information about the companies.

    Click here for Tomi Kilgore’s detailed guide to the wealth of information available for free on the MarketWatch quote page.

    Don’t Miss: These 20 stocks were the biggest losers of 2022

    [ad_2]

    Source link